Combining multi-site magnetic resonance imaging with machine learning predicts survival in pediatric brain tumors.

Journal: Scientific reports
Published Date:

Abstract

Brain tumors represent the highest cause of mortality in the pediatric oncological population. Diagnosis is commonly performed with magnetic resonance imaging. Survival biomarkers are challenging to identify due to the relatively low numbers of individual tumor types. 69 children with biopsy-confirmed brain tumors were recruited into this study. All participants had perfusion and diffusion weighted imaging performed at diagnosis. Imaging data were processed using conventional methods, and a Bayesian survival analysis performed. Unsupervised and supervised machine learning were performed with the survival features, to determine novel sub-groups related to survival. Sub-group analysis was undertaken to understand differences in imaging features. Survival analysis showed that a combination of diffusion and perfusion imaging were able to determine two novel sub-groups of brain tumors with different survival characteristics (p < 0.01), which were subsequently classified with high accuracy (98%) by a neural network. Analysis of high-grade tumors showed a marked difference in survival (p = 0.029) between the two clusters with high risk and low risk imaging features. This study has developed a novel model of survival for pediatric brain tumors. Tumor perfusion plays a key role in determining survival and should be considered as a high priority for future imaging protocols.

Authors

  • James T Grist
    Institute of Cancer and Genomic Sciences, School of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Stephanie Withey
    Institute of Cancer and Genomic Sciences, School of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Oncology, Birmingham Women's and Children's NHS foundation trust, Birmingham, United Kingdom; RRPPS, University Hospitals Birmingham NHS foundation trust, Birmingham, United Kingdom.
  • Christopher Bennett
    Institute of Cancer and Genomic Sciences, School of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Heather E L Rose
    Institute of Cancer and Genomic Sciences, School of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Lesley MacPherson
    Radiology, Birmingham Women's and Children's NHS foundation trust, Birmingham, United Kingdom.
  • Adam Oates
    Radiology, Birmingham Women's and Children's NHS foundation trust, Birmingham, United Kingdom.
  • Stephen Powell
    Institute of Cancer and Genomic Sciences, School of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Jan Novak
    Oncology, Birmingham Women's and Children's NHS foundation trust, Birmingham, United Kingdom; Department of Psychology, School of Life and Health sciences, Aston University, Birmingham, United Kingdom.
  • Laurence Abernethy
    Radiology, Alder Hey Children's NHS foundation trust, Liverpool, United Kingdom.
  • Barry Pizer
    Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
  • Simon Bailey
    Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
  • Steven C Clifford
    Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, University of Newcastle, Newcastle upon Tyne, UK.
  • Dipayan Mitra
    Neuroradiology, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom.
  • Theodoros N Arvanitis
    Institute of Digital Healthcare, WMG, University of Warwick. UK.
  • Dorothee P Auer
    Sir Peter Mansfield Imaging Centre, University of Nottingham Biomedical Research Centre, Nottingham, United Kingdom; NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom.
  • Shivaram Avula
    Department of Radiology, Alder Hey Foundation Trust Hospital, Liverpool, United Kingdom.
  • Richard Grundy
    The Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, United Kingdom.
  • Andrew C Peet
    Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.